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A disintegrine and metalloproteinase 10 (ADAM10) is implicated in synaptic function
through its interaction with postsynaptic receptors and adhesion molecules. Here, we report
that levels of active ADAM10 are increased in Huntington’s disease (HD) mouse cortices
and striata and in human postmortem caudate. We show that, in the presence of
polyglutamine-expanded (polyQ-expanded) huntingtin (HTT), ADAM10 accumulates at the
postsynaptic densities (PSDs) and causes excessive cleavage of the synaptic protein N-
cadherin (N-CAD). This aberrant phenotype is also detected in neurons from HD patients
where it can be reverted by selective silencing of mutant HTT. Consistently, ex vivo delivery
of an ADAM10 synthetic inhibitor reduces N-CAD proteolysis and corrects
electrophysiological alterations in striatal medium-sized spiny neurons (MSNs) of 2 HD
mouse models. Moreover, we show that heterozygous conditional deletion of ADAM10 or
delivery of a competitive TAT-Pro-ADAM10709–729 peptide in R6/2 mice prevents N-CAD
proteolysis and ameliorates cognitive deficits in the mice. Reduction in synapse loss was
also found in R6/2 mice conditionally deleted for ADAM10. Taken together, these results
point to a detrimental role of hyperactive ADAM10 at the HD synapse and provide
preclinical evidence of the therapeutic potential of ADAM10 inhibition in HD.
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Introduction
Huntington’s disease (HD) is an autosomal dominant neurodegen-
erative disorder caused by a polyglutamine (polyQ) expansion in 
the huntingtin (HTT) protein (1, 2). HTT is localized at the synapse, 
where it binds to proteins involved in neurotransmitter transport, as 
well as pre- and postsynaptic organization and function, suggesting 
that it acts as an important regulator of synaptic activity (3, 4). In con-
trast, mutant HTT impairs synaptic function in HD (5, 6). This defect 
occurs early in the disease, in the absence of manifested neuron loss, 
and is most likely the source of emotional, cognitive, learning, and 
memory symptoms in HD patients (7). A key factor in this decline is 
the progressive loss of excitatory corticostriatal glutamatergic input 
to medium-sized spiny neurons (MSNs), which has been linked to 
cell-autonomous and neuronal network mechanisms (5, 6).
A disintegrine and metalloproteinase 10 (ADAM10), a member 
of the large ADAM transmembrane protein family, is expressed at 
high levels in the brain and regulates the molecular organization and 
activity of the excitatory synapse by shedding postsynaptic proteins, 
including N-cadherin (N-CAD), amyloid precursor protein, nectin-1, 
prion protein, neuroligin-1, neural cell adhesion molecule L1, and 
ephrin A2 and A5 (8, 9). ADAM10-mediated shedding of cell-adhe-
sion molecules at the synapse activates a number of processes criti-
cal to proper formation, maintenance, and function of the excitatory 
synaptic circuitries (9). Dendritic spine development, synapse plas-
ticity, memory, and learning all rely on ADAM10 activity (9, 10). The 
importance of ADAM10 for the homeostasis of adult neuronal net-
works has been underscored by the observation that the conditional 
homozygous inactivation of the ADAM10 gene in the neural lineage 
determines profound synaptic phenotypes in the mouse brain (10, 
11). In addition, the overexpression of the enzyme causes unbalance 
in the expression of genes involved in synaptic transmission, and 
moderate neuronal damage (12, 13). Consequently, impairments in 
ADAM10 level and/or activity are detrimental for the human brain. 
ADAM10 has been linked to epilepsy, Alzheimer’s disease (AD), and 
the developmental disorder Fragile X syndrome (9).
Considering the crucial role of ADAM10 in excitatory synaptic 
function and based on previous findings that normal HTT regulates 
its activity in the adult mammalian brain (14), we assessed whether 
the presence of a pathological polyQ tract in HTT could affect the 
level of the active form of ADAM10 in the HD brain, with conse-
quences for the function of the excitatory synapse and cognition 
in HD. In this study, we show that the hyperactivity of ADAM10 
and the increased proteolysis of its synaptic substrate N-CAD are 
decisive neurotoxic events in HD synaptic and cognitive decline.
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between R6/2 and WT mice as HD progressed (Supplemental Figure 
1; supplemental material available online with this article; https://doi.
org/10.1172/JCI120616DS1). Notably, a 56.3% increase of m- AD-
AM10 was found in the R6/2 cerebral cortex (Supplemental Figure 
2, A and B), but not in the cerebellum, which is less affected in HD 
(Supplemental Figure 2, C and D) (2). Notably, levels of m-ADAM10 
were higher in 12 postmortem caudate specimens from HD human 
subjects with Vonsattel grades 3–4 neostriatal atrophy compared with 
5 controls (Figure 1, E and F, and Table 1). Striatal levels of the catalyt-
ically active forms of 2 other members of the ADAM transmembrane 
protein family, ADAM9 and ADAM17, which are enriched in the CNS, 
did not vary between WT and R6/2 mice at 8 weeks of age (Supple-
mental Figure 3, A–D) (9). Similar results were obtained when WT 
and heterozygous zQ175 mice were analyzed (Supplemental Figure 
3, E–H). Finally, m-ADAM10 levels were unaffected in the cerebel-
lum of a mouse model of spinocerebellar ataxia type 3 (SCA3) and 
in 2 transgenic SCA17 rodent models (Supplemental Figure 4, A–F) 
(17–19). Taken together, these results indicate that 2 mouse models 
of HD, but not other polyQ disorders, and human HD brain samples 
exhibit increased levels of the mature form of ADAM10, which is 
restricted to brain areas that predominantly degenerate in HD.
m-ADAM10 accumulates at the synapse and causes N-CAD pro-
teolysis in HD. Having established that the presence of mutant HTT 
leads to increased levels of active ADAM10, we investigated possible 
mechanisms through which this effect may occur. One possibility 
is that HTT may influence ADAM10 function by interacting with 
Results
The mature active form of ADAM10 is increased in HD mouse and 
human striatum. Nascent ADAM10 is produced as an approxi-
mately 95 kDa zymogen and matures into a 60 kDa active protease 
(m- ADAM10) after cleavage of its prodomain, which keeps the 
enzyme in an inactive state, by furin or proconvertase 7 (PC7), in the 
trans- Golgi secretory pathway (9). Initially, we evaluated m-ADAM10 
levels in R6/2 transgenic mice, which bear a genomic fragment con-
taining the promoter and exon 1 of human HTT with 144 CAGs (15). 
These mice present with early onset and fast disease progression: sub-
tle symptoms begin at 6 weeks of age and become more prominent at 
8 to 10 weeks, until the animals die at 13 to 16 weeks (15). Western 
blot performed with an antibody able to detect the mature active 
form of the enzyme (10) revealed a 36.7% increase in m-ADAM10 in 
the striatum of early symptomatic 8-week-old R6/2 mice compared 
with controls (Figure 1, A and B). We further investigated m-ADAM10 
levels in the striatum of heterozygous zQ175 knockin mice in which 
mouse Hdh exon 1 was replaced with a mutated version of human 
HTT exon 1 (16). These mice show a late-onset phenotype and slow-
ly progressive HD pathology (16). We found an 87.5% increase in the 
level of m-ADAM10 in early symptomatic mutant mice at 25 weeks 
of age compared with WT mice, a phenotype that persisted at a later 
time point (54 weeks; Figure 1, C and D). The observed increase in 
striatal m-ADAM10 levels in HD animals was not due to increased 
ADAM10 transcription, as quantitative reverse transcription PCR 
(qRT-PCR) did not reveal differences in the ADAM10 mRNA levels 
Figure 1. The mature active form of ADAM10 is increased in HD mouse and human striatum. (A) Representative Western blot for m-ADAM10 in the stria-
ta of WT (n = 4) and R6/2 mice (n = 5) at 8 weeks of age. (B) Quantification of data shown in A. *P < 0.05, unpaired t test. (C) Representative Western blot 
for m-ADAM10 in the striata of WT and heterozygous zQ175 mice at 25 and 54 weeks of age. (D) Quantification of data shown in C. 25 weeks: n = 6-9 mice/
genotype; 54 weeks: n = 4 mice/genotype. *P < 0.05; ***P < 0.001, unpaired t test. (E) Representative Western blot of m-ADAM10 in the postmortem 
caudate of control (n = 5) and HD patients with Vonsattel grades 3 and 4 of neostriatal atrophy (n = 12). (F) Quantification of data shown in E. ***P < 0.001, 
nonparametric Mann-Whitney 2-tailed U test. α-Tubulin, loading control. Data are represented as mean ± SEM. Arrowheads, nonspecific bands.
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excitatory synapse (20–22). Thus, we evaluated N-CAD proteolysis 
in striatal protein lysates from R6/2 mice at 8, 10, and 12 weeks of 
age. We found that levels of the 36 kDa CTF were 48.4% higher in 
the striatum of R6/2 mice at 8 weeks of age compared with those in 
controls (Figure 2, E and G). Levels of the striatal N-CAD CTF fur-
ther increased by 111% and 162%, respectively, in R6/2 mice at 10 
and 12 weeks of age compared with those in controls (Figure 2, E and 
G). Similarly, a 120.9% increase in N-CAD CTF levels was found in 
the cortex of R6/2 mice at 12 weeks of age compared with those in 
controls (Figure 2, F and G). We concluded that mutant HTT causes 
an accumulation of active ADAM10 at the PSD, leading to increased 
N-CAD proteolysis.
Allele-specific downregulation of mutant HTT prevents increased 
levels of m-ADAM10 and N-CAD proteolysis in human HD neurons. 
To evaluate the link between mutant HTT and the ADAM10/N-
CAD pathway specifically in HD human neurons, we exposed iPS 
cells from control (Q21n1) and HD (Q109n1) patients to a neu-
ronal differentiation protocol (23). A 130% increase in the levels 
of m-ADAM10 and a 97% increase in N-CAD CTF levels were 
observed in DIV30 neurons derived from Q109n1 compared with 
Q21n1 (Figure 3, A–D), reproducing what we previously observed 
in the brains of HD mice and in the human postmortem caudate tis-
sue. We also tested whether downregulation of mutant HTT might 
reduce or reverse its adverse effect on the ADAM10/N-CAD path-
way. We used an allele-specific zinc finger protein repressor type 
A (ZFP-A) under the control of the human synapsin-1 (SYN1) pro-
moter, which allows a specific targeting of the mutant HTT allele 
in neurons. As expected, ZFP-A expression upon 10 days of infec-
ADAM10 in a polyQ-sensitive fashion. We therefore ectopically 
expressed HA-tagged WT or mutant full-length HTT carrying 23 
or 83Q, respectively, with ADAM10-3XFLAG in HEK293T cells, 
followed by immunoprecipitation with an anti-FLAG antibody 
and immunoblotting with an anti-HA antibody. We found that WT 
HTT coimmunoprecipitated with the ADAM10 zymogen and its 
active form while the polyQ-expanded HTT did not (Supplemen-
tal Figure 5). We therefore speculated that, under HD conditions, 
ADAM10 may more promptly localize at the plasma membrane and 
pathologically affect the activity of its synaptic targets. We prepared 
PSD-enriched Triton-X insoluble fraction (TIF) from a pool of corti-
cal and striatal samples collected from WT and R6/2 mice at 6 and 
12 weeks of age. In accordance with our hypothesis, we observed 
that synaptic levels of m-ADAM10 were increased by 102.5% and 
73.5% respectively in R6/2 mice at 6 and 12 weeks of age compared 
with WT mice (Figure 2, A and B). Similarly, synaptic fractions pre-
pared from postmortem caudate tissues from individuals with ear-
ly and late-stage HD showed an increase in m-ADAM10 compared 
with healthy controls (Figure 2, C and D). The increased pool of 
m-ADAM10 at the synapse suggests that processing of its synaptic 
substrates may be increased in the HD brain. Among the ADAM10 
targets, N-CAD plays a central role in the regulation of cell-cell 
adhesion, synapse morphology, and plasticity (20, 21). An excessive 
presence of ADAM10-mediated N-CAD proteolysis in the brain, 
documented by increased levels of the 36 kDa N-CAD C-terminal 
fragment (CTF), affects synaptic connectivity because it compro-
mises adhesion between the pre- and postsynaptic membrane and 
reduces the overall long-term stability and neurotransmission of the 
Table 1. HD patient demographics
ID sample Vonsattel grade Age (yr) Sex PMI (h) Region
04969 Control 60 F 21.67 Caudate
08704 Control 70 M 23.50 Caudate
10090 Control 52 M 13.12 Caudate
13112 Control 63 M 17.92 Caudate
13574 Control 53 M 21.06 Caudate
16413 1 68 F 8.30 Caudate
13777 1 52 F 24.40 Caudate
01517 1 55 M 21.70 Caudate
08302 2 76 M 19.90 Caudate
18185 2 55 F 22.60 Caudate
04466 2 54 M 21.80 Caudate
00950 3 69 M 10.10 Caudate
10314 3 70 M 18.00 Caudate
18554 3 60 M 14.90 Caudate
18743 3 53 M 17.80 Caudate
19252 3 58 F 15.40 Caudate
06034 4 35 M 23.90 Caudate
18263 4 54 F 21.70 Caudate
12558 4 50 F 24.30 Caudate
10094 4 33 M 22.00 Caudate
00497 4 48 F 7.58 Caudate
15530 4 64 F 18.20 Caudate
01824 4 45 M 21.60 Caudate
PMI, Postmortem interval; F, female; M, male. Samples were obtained from the HBTRC. 
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blood-brain barrier (BBB), we acutely exposed corticostriatal brain 
slices from 11-week-old control and R6/2 mice to increasing doses 
of compound for 45 minutes. GI254023X at a concentration of 1, 10, 
100, and 1000 nM was able to significantly prevent the excessive pro-
duction of the N-CAD CTF in R6/2 brain slices compared with R6/2 
vehicle-treated slices (Figure 4, A and B). To test the functional effect 
of ADAM10 inhibition at the HD excitatory synapses, we incubated 
acute brain slices from 11-week-old R6/2 and heterozygous 54-week-
old zQ175 mice in the presence of 50 nM GI254023X for 45 minutes, 
followed by whole-cell patch clamp to record basic membrane prop-
erties and spontaneous excitatory post-synaptic currents (sEPSCs) in 
MSNs. As previously shown (25, 26), we confirmed that membrane 
capacitance (Cm) is reduced, input resistance (Rin) increased, and 
membrane resting potential (Vm) depolarized in R6/2 and zQ175 
MSNs compared with WT MSNs, reflecting smaller cell size and 
abnormal ion channel expression in HD MSNs (Supplemental Figure 
6, A–F, and Supplemental Table 1). Upon GI254023X administration, 
these parameters remained unchanged (Supplemental Figure 6, A–F, 
and Supplemental Table 1). We conclude that GI254023X does not 
change the cell size, ion channel expression, and/or activity on the 
tion induced a downregulation of total HTT mRNA in Q109n1 
neurons that was not observed with GFP expression (Figure 3E). 
We also observed that levels of m-ADAM10 and N-CAD CTF 
were restored almost up to physiological levels in Q109n1 neu-
rons infected with ZFP-A, while infection with a GFP vector was 
ineffective (Figure 3, A–D). These experiments indicate that the 
observed increased m-ADAM10 and N-CAD levels in HD human 
neurons are directly dependent on the expression of mutant HTT.
Administration of the ADAM10 synthetic inhibitor GI254023X res-
cues synaptic functional defects in HD mice. We next determined wheth-
er normalizing ADAM10 rescues N-CAD cleavage and electrophysi-
ological synaptic phenotypes in HD mice. To this end, we employed 
GI254023X, a selective hydroxamate inhibitor that chelates the Zn2+ 
of the protease active site and has been used successfully in the past 
to block ADAM10 catalytic activity in vitro in mammalian cells and in 
vivo in zebrafish (14, 24). We further confirmed GI254023X specifici-
ty for ADAM10 versus ADAM17 by in vitro enzymatic assay with a flu-
orogenic ADAM substrate showing it possesses 122.4-fold increased 
selective inhibitory potency for ADAM10 (IC50 = 13.67 nM) compared 
with ADAM17 (IC50 = 1673 nM). As GI254023X does not pass the 
Figure 2. m-ADAM10 accumulates at the synapse and causes N-CAD proteolysis in the HD brain. (A) Representative Western blot for m-ADAM10 on PSDs 
from a pool of n = 3 cortices and striata of WT and R6/2 mice at 6 and 12 weeks of age. β-III Tubulin, loading control; PSD95, PSDs marker. (B) Quantifica-
tion of data in A. Data are represented as mean ± SEM of n = 3 biological replicates in which a pool of n = 3 mice/genotype was tested. *P < 0.05; **P < 
0.01, unpaired t test. (C) Representative Western blot for m-ADAM10 on PSDs prepared from a pool of n = 3 postmortem caudate tissues of control and 
HD patients with Vonsattel grades 1, 2, and 4 of neostriatal atrophy. (D) Quantification of data in C. Data are represented as mean ± SEM of n = 4 technical 
replicates. **P < 0.01; ***P < 0.001, 1-way ANOVA with Bonferroni’s post hoc test. (E) Representative Western blot of N-CAD CTF in striata from WT and 
R6/2 mice at 8, 10. and 12 weeks of age. α-Tubulin, loading control. (F) Representative Western blot of N-CAD CTF in cortices from WT and R6/2 mice at 12 
weeks of age. α-Tubulin, loading control. (G) Quantification of results shown in E and F. Striatum, 8 weeks: n = 4–5 mice/genotype; 10 weeks: n = 3 mice/
genotype; #2 R6/2 is an outlier excluded from data analyses. 12 weeks: n = 3 mice/genotype. Cortex, 12 weeks: n = 3–4 mice/genotype. Data are represent-
ed as mean ± SEM. *P < 0.05; **P < 0.01, unpaired t test.
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TAT-Pro-ADAM10709–729 peptide prevents N-CAD proteolysis and 
cognitive decline in HD mice. Binding of ADAM10 to synapse associ-
ated protein 97 (SAP97) is required for inserting ADAM10 into the 
synaptic membrane (27). SAP97 promotes ADAM10 trafficking at 
the excitatory synapse by a direct interaction between its Src homol-
ogy 3 (SH3) domain and the proline-rich domains of ADAM10 (27). 
We investigated whether reducing synaptic trafficking of ADAM10 
by disrupting the ADAM10/SAP97 complex could prevent N-CAD 
cleavage and synaptic phenotypes in R6/2 mice (27, 28). To this end, 
we employed a cell-permeable peptide (TAT-Pro-ADAM10709–729) 
that contains the proline-rich domain of ADAM10 and competes 
with endogenous ADAM10 for the binding to SAP97 (28). As a 
control, animals were injected with the TAT-Ala-ADAM10709–729 
peptide, which is unable to bind SAP97 because prolines are substi-
tuted by alanines. WT and R6/2 mice at 12 weeks of age received 
2 i.p. injections 24 hours apart of either TAT-Pro-ADAM10709–729 or 
TAT-Ala-ADAM10709–729 peptide (2 nmol/g) diluted at 0.5 mg/ml in 
sterile saline solution (Figure 5A). We found that i.p. injection of the 
TAT-Pro-ADAM10709–729 in 12-week-old R6/2 mice reduced levels 
of synaptic m-ADAM10 compared with TAT-Ala-ADAM10709–729–
treated mice (Figure 5, B and C). Moreover, Western blots revealed 
that TAT-Pro-ADAM10709–729 was effective in reducing the exces-
sive levels of N-CAD CTF in the R6/2 striatum (Figure 5, D and 
E) and cortex (Figure 5, F and G), while the control peptide had no 
effect (Figure 5, D–G). We then employed the cued fear condition-
ing test to evaluate whether treatment with TAT-Pro-ADAM10709–729 
could improve cognitive experience in R6/2 mice. On day 1, animals 
were trained to associate conditioned stimuli (CS, environment and 
plasma membrane. As reported previously (25, 26), the spontaneous 
glutamatergic synaptic activity of MSNs is affected, and with HD 
progression, the sEPSC frequency, but not amplitude, is reduced in 
R6/2 and zQ175 MSNs compared with WT MSNs (Figure 4, C and D, 
Supplemental Figure 7, A and B, and Supplemental Table 2). When 
GI254023X was applied to both R6/2 and zQ175 brain slices, a sig-
nificant rescue of sEPSC frequency occurred compared with that in 
untreated R6/2 and zQ175 MSNs (Figure 4, C and D). sEPSCs may 
be produced by the release of synaptic vesicles (SVs) following either 
the arrival of a spontaneous action potential at the presynaptic termi-
nal or by stochastic SVs release. By applying the Na+ channel blocker 
tetrodotoxin (TTX), we could measure action potential–independent 
postsynaptic events defined miniature EPSCs (mEPSCs), the fre-
quency of which reflects the presynaptic probability of releasing SVs 
and is also correlated to the number of synapses. We found that mEP-
SC frequency was reduced in R6/2 MSNs compared with WT MSNs 
(Figure 4E). Notably, treatment with GI254023X determined a sig-
nificant rescue in mEPSC frequency of R6/2 MSNs compared with 
untreated R6/2 MSNs (Figure 4E), consistent with ADAM10 inhibi-
tion acting presynaptically to increase the probability of presynaptic 
vesicles release. mEPSC amplitude, which is an indicator of post-
synaptic responsiveness, was not affected in R6/2 MSNs before and 
after treatment (Supplemental Figure 7C and Supplemental Table 3), 
indicating that the quantal size, the number and structure of postsyn-
aptic receptors, and the location of synaptic contacts are not affected 
by mutant HTT, nor by GI254023X. Collectively, these data indicate 
that inhibition of ADAM10 activity improves functional deficits of the 
excitatory HD synapse.
Figure 3. Mutant HTT suppression prevents increased levels of m-ADAM10 and N-CAD proteolysis in human HD neurons. Control (Q21n1) and HD 
(Q109n1) iPS cells were exposed to neuronal differentiation. A synthetic ZFP targeting mutant HTT (ZFP-muHTT) was delivered to Q109n1 at DIV20 and 
DIV23, and GFP was used as control. Levels of m-ADAM10, N-CAD CTF, and HTT mRNA were analyzed at DIV30 of neuronal differentiation. (A) Represen-
tative Western blot for m-ADAM10 in neurons generated from Q21n1 and Q109n1 iPS cells infected with ZFP-muHTT and GFP. α-Tubulin, loading control (B) 
Quantification of data in A. *P < 0.05; **P < 0.01; ***P < 0.001, 1-way ANOVA followed by Bonferroni’s post hoc test. (C) Representative Western blot for 
N-CAD CTF in neurons from Q21n1 and Q109n1 iPS cells infected with ZFP-muHTT and GFP. α-Tubulin, loading control. (D) Quantification of data in C.  
*P < 0.05; **P < 0.01, 1-way ANOVA with Bonferroni’s post hoc test. (E) qPCR for total HTT mRNA in neurons from Q21n1 and Q109n1 iPS cells infected 
with ZFP-muHTT and GFP. ***P < 0.001, 1-way ANOVA with Bonferroni’s post hoc test. Data are represented as mean ± SEM of n = 3 technical replicates.
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acoustic tone), with an aversive stimulus (AS, electric foot shock). 
On day 2, animals were left in their housing rooms to rest, and on 
day 3 they were exposed to a different environment in the presence 
of the sole acoustic tone (cued stage). In cued stage, mice gener-
ally demonstrate a freezing response if they remember and asso-
ciate the acoustic tone with the AS. Latency to freeze was longer 
with R6/2-TAT-Ala-ADAM10709–729 in cued stage compared with 
WT-TAT-Ala-ADAM10709–729 (Figure 5H), indicating that R6/2 mice 
require a longer time to associate the CS with the AS. In line with 
these data, a shorter freezing time was found with R6/2-TAT-Ala-
ADAM10709–729 in cued stage (Figure 5I), confirming that R6/2 mice 
fail to remember an association between CS and AS. Notably, R6/2-
TAT-Pro-ADAM10709–729 mice exhibited a shorter latency to freeze 
than R6/2-TAT-Ala-ADAM10709–729 and a longer freezing time in 
cued stage (Figure 5, H and I). Together, these data suggest that 
reduction of ADAM10 trafficking to the postsynaptic compartment 
alleviates cognitive impairments in HD mice.
Genetic reduction of ADAM10 corrects synaptic loss and cog-
nitive decline in R6/2 mice. To further evaluate the therapeutic 
potential of ADAM10 inhibition in HD, we crossed R6/2 mice 
with CaMKIIα-Cre:Adam10Flox/+ mice (A10cKO), an ADAM10 
heterozygous conditional KO mouse line limiting ADAM10 inac-
tivation to the postnatal forebrain, to obtain R6/2-A10cKO mice 
(Figure 6A) (10). Western blot showed that synaptic m-ADAM10 
(Figure 6, B and C) and N-CAD CTF levels (Figure 6, D and E) in 
R6/2-A10cKO striatum were fully restored to the amount that is 
found in WT animals. Synapse loss correlates robustly with cog-
nitive decline in HD patients and HD animal models (29, 30). To 
determine whether ADAM10 inhibition prevents synapse loss, 
we examined the excitatory synapse density in striatal sections 
by using serial block-face scanning electron microscopy (SBF-
SEM) imaging and high-resolution 3D reconstruction of the syn-
apse. Our blinded ultrastructural analyses revealed 28% loss of 
striatal glutamatergic synapses in 13-week-old R6/2 mice com-
pared with controls (Figure 6, F, G, and J), which was rescued by 
ADAM10 heterozygous deletion in R6/2-A10cKO mice (Figure 6, 
H and J). The number of glutamatergic synapses was not affected 
in A10cKO mice (Figure 6, I and J). We then used transmission 
electron microscopy (TEM) to examine pre- and postsynaptic 
densities (PSDs), which are located at the heads of spines and 
are critical for synaptic function. In line with electrophysiological 
data, our TEM morphological analyses revealed that, although 
postsynaptic parameters were not affected (Supplemental Fig-
ure 8, A and B), SVs density and number of docked vesicles were 
decreased in R6/2 presynaptic compartment (Figure 6, K and L). 
Notably, these structural deficits were rescued by heterozygous 
Figure 4. Treatment with the ADAM10 inhibitor GI254023X reduces N-CAD proteolysis and rescues electrophysiological defects of the excitatory 
synapse in HD. (A) Representative Western blot for N-CAD on corticostriatal brain slices from 4 untreated 11-week-old WT mice and 1 R6/2 mouse acutely 
treated with vehicle and GI254023X at concentrations of 1, 10, 100, and 1000 nM. α-Tubulin, loading control. (B) Quantification of data shown in A. WT,  
n = 8; R6/2 treated with GI254023X or vehicle, n = 3–5. ***P < 0.001, 1-way ANOVA with Bonferroni’s post hoc test. (C) sEPSCs frequencies recorded from 
striatal MSNs of WT and R6/2 mice at 11 weeks of age. WT, n = 17; R6/2-untreated, n = 15; R6/2-GI254023X-50nM, n = 16. **P < 0.01; ***P < 0.001, 1-way 
ANOVA with Bonferroni’s post hoc test. (D) sEPSC frequencies recorded from striatal MSNs of WT and zQ175 mice at 54 weeks of age. WT, n = 7; zQ175- 
untreated, n = 7; zQ175-GI254023X-50nM, n = 7. *P < 0.05; *** P < 0.001, 1-way ANOVA with Bonferroni’s post hoc test. (E) mEPSC frequencies recorded 
from striatal MSNs of WT and R6/2 mice at 11 weeks of age. WT, n = 7; R6/2-untreated, n = 7; and R6/2-GI254023X-50nM, n = 8. *P < 0.05; ***P < 0.001, 
1-way ANOVA with Bonferroni’s post hoc test. Data are represented as mean ± SEM.
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suppression of the ADAM10 gene (Figure 6, K and L). Taken 
together, these data indicate that reduced synapse density and 
presynaptic pathology in HD are due to increased ADAM10 activ-
ity. To validate the effect of ADAM10 inhibition on HD cognitive 
phenotypes, WT, R6/2, R6/2-A10cK10, and A10cKO mice were 
tested by contextual and cued fear conditioning. We found that 
9-week-old and 13-week-old R6/2 mice require a longer time to 
associate the CS (environment and acoustic tone) with the AS 
(electric foot shock) because their latency to freeze was higher 
in both the contextual (Figure 6M) and cued stages (Figure 6N) 
compared with control groups (WT and A10cKO). In line with 
these data, a shorter freezing time was found in R6/2 mice under 
both conditions, which became significant at the cued stage (Fig-
ure 6, O and P). In contrast, 9-week-old and 13-week-old R6/2-
A10cKO mice showed a significantly shorter latency to freeze 
than R6/2 mice at both the contextual (Figure 6M) and cued stag-
Figure 5. TAT-Pro-ADAM10709–729 peptide normalizes N-CAD proteolysis and rescues cognitive deficits in R6/2 mice. (A) TAT-Pro-ADAM10709–729 (TAT-Pro) 
interferes with ADAM10/SAP97 interaction and impairs ADAM10 synaptic trafficking. TAT-Ala-ADAM10709–729 (TAT-Ala), inactive peptide. 12-week-old WT and 
R6/2 mice received 2 i.p. injections of TAT-Pro or TAT-Ala at 2 nmol/g 24 hours apart. Saline solution, vehicle. Synaptic level of m-ADAM10, N-CAD proteoly-
sis, and cognitive function were monitored 24 hours after the second i.p. injection. (B) Representative Western blot for m-ADAM10 in striatal synaptic frac-
tions of 12-week-old WT and R6/2 mice treated with TAT-Pro or TAT-Ala. β-III Tubulin, loading control. Arrowhead, nonspecific band. Lanes were run on the 
same gel, but were noncontiguous. (C) Quantification of data in B. WT-TAT-Ala, n = 4; R6/2-TAT-Ala, n = 5; R6/2-TAT-Pro, n = 6. *P < 0.05; **P < 0.01, 1-way 
ANOVA with Bonferroni’s post hoc test. (D) Representative Western blot showing effects of TAT peptides on N-CAD proteolysis in the striata of R6/2 mice. 
α-Tubulin, loading control. (E) Quantification of data in D. WT-saline, n = 3; WT-TAT-Ala, n = 3; R6/2-saline, n = 3; R6/2-TAT-Ala, n = 6; R6/2-TAT-Pro, n = 6.  
*P < 0.05; **P < 0.01; ***P < 0.001, 1-way ANOVA with Bonferroni’s post hoc test. (F) Representative Western blot showing effects of TAT peptides on 
N-CAD proteolysis in the cortices of R6/2 mice. α-Tubulin, loading control. (G) Quantification of data shown in F. WT-saline, n = 4; WT-TAT-Ala, n = 3; 
R6/2-saline, n = 3; R6/2-TAT-Ala, n = 4; R6/2-TAT-Pro, n = 4. *P < 0.05; **P < 0.01, 1-way ANOVA with Bonferroni’s post hoc test. (H, I) Effect of TAT peptides 
in the fear conditioning test in WT and R6/2 mice at 12 weeks of age. WT-TAT-Ala, n = 9; R6/2-TAT-Ala, n = 8; R6/2-TAT-Pro, n = 8. Cued fear response evalu-
ated as latency to freeze (H) and freezing time (I). *P < 0.05; **P < 0.01, 1-way ANOVA with Newman-Keuls. Data are represented as mean ± SEM.
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Discussion
Although HD has been classically considered as a neurodegen-
erative disorder characterized by voluntary movement, cognitive 
decline is now receiving increased attention, as it is highly inval-
idating for the patients. Considerable efforts have been invested 
es (Figure 6N) and a longer freezing time at the cued stage (Fig-
ure 6P). No improvement in RotaRod performance was observed 
in R6/2-A10cKO mice (Supplemental Figure 9). Taken together, 
these data indicate that increased ADAM10 activity in HD con-
tributes to cognitive but not to motor decline.
Figure 6. ADAM10 heterozygous deletion in the forebrain rescues synapse loss and cognitive decline in R6/2 mice. (A) CaMKIIα-Cre:Adam10Flox/+(A10cKO) mice 
were crossed with R6/2 mice to obtain R6/2:CaMKIIα-Cre:Adam10Flox/+(R6/2-A10cKO). (B) Representative Western blot for synaptic m-ADAM10 in the striata 
of WT, R6/2, and R6/2-A10cKO at 13 weeks of age. β-III Tubulin, loading control. Lanes were run on the same gel, but were noncontiguous. (C) Quantification of 
data in B. n = 3 mice/genotype, *P < 0.05, 1-way ANOVA with Bonferroni’s post hoc test. (D) Western blot of CTF N-CAD in the striata of WT, R6/2, and R6/2-
A10cKO at 13 weeks of age. α-Tubulin, loading control. (E) Quantification of data in D. n = 3 mice/genotype. *P < 0.05; **P < 0.01, 1-way ANOVA with Bonferroni’s 
post hoc test. (F–I) Representative SBF-SEM segmentation and reconstruction of excitatory synapses (green) with their PSD (yellow) in 90 μm³ of striatum, and 
TEM images of striatal synaptic profile of WT (F), R6/2 (G), R6/2-A10cKO (H), and A10cKO (I) mice at 13 weeks of age. Scale bar: 100 nm. (J) Quantification of 
excitatory synapse density in 800 μm3 of striatal tissue/mouse in n = 3 mice/genotype. **P < 0.01; ***P < 0.001, 1-way ANOVA with Bonferroni’s post hoc test. 
(K) Quantification of SVs density and (L) docked vesicles/μm AZ in n = 3 mice/genotype. At least n = 60 excitatory synapses/genotype were analyzed.  
*P < 0.05; **P < 0.01; ***P < 0.001, 1-way ANOVA with nonparametric Dunn’s multiple comparison test. (M–P) Fear conditioning test on WT, R6/2, R6/2-
A10cKO, and A10cKO mice at 9 and 13 weeks of age. n = 6–8 mice/genotype. (M, N) Contextual and cued fear responses evaluated as latency to freeze and  
(O, P) freezing time. *P < 0.05; **P < 0.01; ***P < 0.001, 1-way ANOVA with Newman-Keuls post hoc test. Data are represented as mean ± SEM.
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In summary, our findings indicate that interfering with 
ADAM10 activity may be a powerful strategy for preventing syn-
aptic dysfunction and cognitive decline in HD. We also specu-
late that destabilization of the synaptic cell adhesion contacts by 
increased ADAM10 activity could render the HD synapses unsta-
ble and less responsive to drugs, especially those acting on neu-
rotransmitters and receptor systems impaired in the disease (32). 
Increased ADAM10 activity in HD and the consequently disrupt-
ed synaptic structure may help explain why these drugs have so far 
been largely inefficacious in clinical trials.
Methods
Human tissues. All postmortem human tissue was obtained from the 
Harvard Brain Tissue Resource Center (HBTRC) (Belmont, Massa-
chusetts, USA). Patient information is present in Table 1.
Rodent models. WT and R6/2 mice (B6CBAF1/J) were purchased 
from the Jackson Laboratory (15). Heterozygous Adam10 floxed mice 
(Adam10Flox/+) (C57BL/6J × 129 S6) and CaMKIIalpha-Cre recombi-
nase transgenic mice (C57BL/6J × 129 S6) were generated as described 
before (10). Brain tissues from WT and zQ175 (C57BL/6J) mice were 
obtained from the CHDI Foundation (16). SCA3 mice (B6-Tg(Prnp-
ATXN3*)71-OR/OR), SCA17 mice (B6CBA(FVB)-Tg(Prnp-TBP*)71-
16Xjl/J), and SCA17 rats (Crl:CD(SD)-Tg(Prnp-TBP*)64-HPN/HPN) 
were generated as described before (17–19). Both male and female 
mice were used for biochemical and behavioral analyses.
Cell lines. HEK293T cells (ATCC) were maintained in DMEM 
(Gibco, Thermo Fisher Scientific, catalog 31885-023) supplemented 
with 10% FBS (Gibco Thermo Fisher Scientific, catalog 10270-106) 
and 1% penicillin/streptomycin (Gibco Thermo Fisher Scientific, cata-
log 15140-122). Nonintegrating HD (Q109n1) and control (Q21n1) iPS 
cell lines were generated in the C. Svendsen laboratory at Cedars-Sinai 
Medical Center (33). The lines/clones used in this study were regular-
ly tested for karyotype and maintained as mycoplasma free. iPS cells 
were maintained in mTeSR1 medium (STEMCELL Technologies, cat-
alog 85850) and plated on Matrigel (Trevigen, catalog 3434-001-02).
Neuronal differentiation of iPS cells. Cells were plated at a density of 0.6 
× 105 cells/cm2 on Matrigel-coated dishes in mTeSR1 with 10 μM ROCK 
inhibitor (MilliporeSigma, catalog Y-27632). Cultures were expanded for 
2 days until cells reached 70% confluency. DMEM/F12 (Gibco, Ther-
mo Fisher Scientific, catalog 11320033) supplemented with N2 and B27 
(Gibco, Thermo Fisher Scientific, catalog 17502048 and 17504044), 10 
μM SB431542, and 500 nM of LDN (provided by Evotec) were used as 
starting differentiation medium. Medium was replaced every day. At day 
15, the cells were detached by Accutase (MilliporeSigma, catalog SF006) 
and replated on Matrigel at a density of 2.5 × 104 cells/cm2. The cells were 
differentiated in terminal differentiation medium by adding 30 ng/mL 
BDNF (PrepoTech, catalog 450-02) together with N2 and B27.
ZFPs cloning strategy and iPS cell infection. The coding sequences 
for the ZFP-A repressor were cut from the previously described FUW- 
tetO-ZFP plasmids using the restriction enzymes AfeI and NheI (23). 
The sequences were then subcloned into the lentiviral plasmid pLV-
hSyn-RFP (Addgene, catalog 22909) by replacing the RFP sequence 
through compatible digestion with restriction enzymes PmeI and XbaI. 
iPS cells were differentiated as described above and infected or not twice 
with the lentiviral supernatant coding for ZFP-A or GFP at DIV20 and 23 
using 5 μl/well in 12-well plates. The viruses were diluted in 1 ml terminal 
differentiation medium with 4 μg/ml polybrene (MilliporeSigma, cata-
to determine which components of the altered corticostriatal syn-
apse contribute to cognitive deficits. Preclinical research revealed 
that some available compounds attenuate synaptic dysfunction 
and cognitive decline in HD mouse models, but human trials have 
been so far disappointing, demonstrating little or no therapeutic 
benefits and substantial side effects.
Here, we propose ADAM10 as a target of interest in HD 
due to its inherent structural and functional role in synaptic 
connectivity. Our study reveals that overabundance of active 
ADAM10 and, as a consequence, the proteolysis of the syn-
aptic cell adhesion protein N-CAD, mediates mutant HTT- 
associated synaptic and cognitive dysfunction. In the HD brain, 
active ADAM10 accumulates at the PSDs and causes excessive 
N-CAD cleavage. These molecular events determine loss of 
excitatory synaptic contacts and reduce the density of presyn-
aptic vesicles and the number of vesicles ready for release, ulti-
mately leading to excitatory synapse deficiencies and cognitive 
decline in HD. Relevant to the disease, we found that the level 
of active ADAM10 is also increased in the human HD caudate 
tissues and in HD neurons generated from iPS cells, the latter 
phenotype being reverted by selective suppression of mutant 
HTT. These findings suggest that, similar to the mouse model, 
increased ADAM10 activity may also have a detrimental effect 
on synaptic structure and function in patients. Future studies 
are needed to determine whether increased ADAM10 activity 
is strictly related to synaptic dysfunction or whether it contrib-
utes to other disease phenotypes. Identifying novel ADAM10 
interactors and substrates may help in deciphering the impact 
of ADAM10 on HD pathogenesis.
Our data also suggest that molecular, pharmacological, and 
genetic targeting of the ADAM10 can be neuroprotective in HD. 
Therapeutic targeting of ADAM10 with the hydroxamate inhibi-
tor GI254023X is able to reduce excessive N-CAD proteolysis in 
the striatum ex vivo and to correct electrophysiological defects 
in MSNs from 2 HD mouse models. Consistently, normalizing 
ADAM10 activity in the HD brain by in vivo delivery of a compet-
itive TAT-Pro-ADAM10709–729 peptide alleviates cognitive decline 
in HD mice. We further validated our findings by showing that 
conditional heterozygous deletion of ADAM10 in the forebrain 
prevents synapse loss and synaptic ultrastructural defects in the 
striatum of HD mice, reducing cognitive impairment.
Our ex vivo and in vivo evidence suggests that safe, selective, 
and brain-penetrant peptides or drug-like molecules specifically 
designed to interfere with ADAM10 deserve to be explored in 
HD. Although 50% genetic ablation of ADAM10 in the forebrain 
is well tolerated in WT mice, the doses of ADAM10 inhibitors and 
therapeutic windows of application have to be defined carefully 
in order to preserve a physiological concentration of the active 
enzyme (31). Caution is needed because a reduction in ADAM10 
activity below 50% causes severe disruption of synaptic archi-
tecture and function and increased formation of Aβ peptides in 
mice (10). ADAM10 is expressed almost ubiquitously in the body 
and plays important roles in peripheral tissues beyond the brain 
(9). Selectively targeting the ADAM10/SAP97 complex in the 
HD brain could finely tune ADAM10 shedding activity toward 
N-CAD, overcoming problems and unwanted side effects related 
to systemic inhibition of the protease.
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atal and cortical tissues. For behavioral analysis, mice were tested for 
the fear-conditioning test 24 hours after the second injection.
Generation of R6/2-A10cKO mice. R6/2 mice (B6CBAF1/J) were 
generated by crossing R6/2 males with WT females (B6CBAF1/J). The 
A10cKO colony was maintained by crossing heterozygous floxed mice 
(Adam10Flox/+) (C57BL/6J × 129 S6) with CaMKIIalpha-Cre recombinase 
transgenic mice (C57BL/6J × 129 S6). A10cKO exhibited a normal phe-
notype and a normal fertility. From the crossing between heterozygous 
A10cKO and R6/2 mice, we tested 4 genotypes of the F1, including WT, 
R6/2, R6/2-A10cKO, and A10cKO, which are on the same mixed genetic 
background. Mice were genotyped as previously described (10).
Behavioral tests. Motor and cognitive functions were assessed by the 
same operator blinded to the treatment. A group of animals was tested 
at 6, 10, and 12 weeks of age for the assessment of the motor behavior 
by the RotaRod test. Another group of animals was tested at 9 and 13 
weeks of age for the assessment of cognitive deficits by the fear condi-
tioning test. For RotaRod, the test was performed using the accelerat-
ing RotaRod apparatus (Ugo Basile, catalog 47600). Mice were moved 
to the RotaRod room at least 30 minutes before starting the test. Mice 
were tested 2 days a week. On each testing day, mice were first trained 
at a constant speed of 4 rpm for 5 minutes on the apparatus. Mice were 
then tested in 3 consecutive sessions with acceleration from 4 to 40 
rpm in 5 minutes. The time at which mice fell from the rotating bar was 
recorded, for a maximum of 5 minutes. The best performance of each 
day was recorded, and the average between the 2 trials was reported in 
the graph. Contextual and cued fear conditioning was performed using 
the Fear Conditioning System (Ugo Basile, series 46000). WT-TAT-
Ala-ADAM10709–729, R6/2-TAT-Ala-ADAM10709–729, and R6/2-TAT-Ala-
ADAM10709–729 mice were tested by cued fear conditioning according 
to the following protocol: on day 1, mice were transferred to the behav-
ioral room at least 30 minutes before starting the test. The conditioned 
stimulus (CS) was a 10-second 3.5 kHz tone delivered 150 seconds after 
the beginning of the test. The unconditioned stimulus (US) was a 2-sec-
ond 0.5 mA footshock that coterminated with the CS. The conditioning 
was repeated 3 times, every 150 seconds. After the last conditioning, 
animals were let in the same chamber for 150 seconds, and then they 
were placed in their cage. During day 2, animals were left in their hous-
ing room to rest. On day 3, cued fear conditioning was assessed using a 
modified conditioning chamber obtained by attaching patterned con-
texts on the walls and floor. Once mice were placed in this modified 
chamber, a protocol similar to that of day 1 was applied, except for the 
electrical footshock that was not administered. Freezing of animals 
was assessed and recorded during the tone activation in order to focus 
the analysis during the CS. Latency to freeze and time of freezing were 
recorded. WT, R6/2, R6/2-A10cKO, and A10cKO mice were tested 
by contextual and cued fear conditioning according to the following 
protocol: on day 1, mice were trained as described above for WT and 
R6/2 mice treated with TAT peptides. On day 2, contextual memory 
was assessed by placing animals in the same conditioning chamber for 
5 minutes and measuring freezing response in terms of time of freezing 
and latency to freeze. On day 3, cued fear conditioning was assessed 
as described above for WT and R6/2 mice treated with TAT peptides.
Western blot for iPS cells and mouse and human tissue. Samples were 
lysed in RIPA buffer (50 mM Tris-HCl pH 8, 150 mM NaCl, 0.1% SDS, 
1% Nonidet P40, 0.5% sodium deoxycholate) with 1 mM PMSF and 
1× protease inhibitor cocktail (Thermo Scientific, catalog 1861281). 
Lysates were cleared by centrifugation for 30 minutes at 12,000 g and 
log TR1003-G), and cells were exposed for 18 hours. At DIV30, infected 
and untreated cells were detached using Accutase (EMD Millipore, cata-
log SF006) and centrifuged for 3 minutes at 8000 g for storage at –80°C.
Lentivirus production. HEK293NT cells (ATCC) were used for 
viral production and cultured in DMEM (Gibco, Thermo Fisher 
Scientific, catalog 31885-023) supplemented with 10% FBS (Gib-
co, Thermo Fisher Scientific, catalog 10270-106), 0,5% penicillin/
streptomycin (Gibco, Thermo Fisher Scientific, catalog 15140-122), 
2 mM glutamine (Euroclone, catalog ECB3000D), 1 mM sodium 
pyruvate (Gibco, Thermo Fisher Scientific, catalog 11360-039), and 
1% nonessential amino acids (Gibco, Thermo Fisher Scientific, cata-
log 11140-035). For the production of lentiviral supernatants for the 
pLV-hSyn-ZFP-A and pLV-hSyn-GFP constructs, cells were plated 
on gelatin-coated dishes at a density of 45,000 cells/cm2 and were 
transfected on the following day with Lipofectamine 3000 (Invitro-
gen, Thermo Fisher Scientific, catalog L300-015) according to the 
manufacturer’s instructions. The single donor plasmid was cotrans-
fected with the third generation packaging vectors pMDLg/pRRE 
(Addgene, catalog 12251), pRSV-Rev (Addgene, catalog 12253), and 
pMd2.G (Addgene, catalog 12259) at a 4:2:1:1 ratio, respectively. The 
transfection mix was removed after overnight incubation, and fresh 
medium was supplied to the cells. The supernatant was collected 48 
hours and 72 hours after transfection and centrifuged at 60,000 g for 
2 hours; concentrated viral particles were resuspended in PBS and 
stored at –80°C.
HD mice genotyping. Genotyping of R6/2 (B6CBAF1/J) and 
zQ175 (C57BL/6J) mouse colonies (~150 CAG and 175 repeats, 
respectively) was performed by PCR of genomic DNA obtained 
from tail samples (Nucleo Spin Tissue, Macherey- Nagel, catalog 
740952.250) at weaning and following sacrifice for verification. 
CAG repeats of R6/2 mice were sized by using the following PCR 
primers: forward: ATGAAGGCCTTCGAGTCCCTCAAGTCCTTC; 
reverse: GGCGGCTGAGGAAGCTGAGGA. Cycling conditions 
were 94°C for 90 seconds, 35 cycles × (94°C for 60 seconds, 65°C for 
45 seconds, 72°C for 60 seconds), 72°C for 7 minutes. CAG repeats 
of zQ175 mice were sized by using the following PCR primers: for-
ward: CATTCATTGCCTTGCTGCTAAG; reverse: CTGAAAC-
GACTTGAGCGACTC. Cycling conditions were 94°C for 10 min-
utes, 30 cycles × (96°C for 30 seconds, 57°C for 30 seconds, 72°C for 
30 seconds), 72°C for 7 minutes.
Treatment of mice with TAT peptides. WT and R6/2 mice at 12 
weeks of age received 2 i.p. injections 24 hours apart of either TAT-
Pro-ADAM10709–729 (2 nmol/g) or TAT-Ala-ADAM10709–729 peptide (2 
nmol/g) diluted at 0.5 mg/ml in sterile saline solution. The cell-per-
meable peptide TAT-Pro-ADAM10709–729 was obtained by linking the 
11 amino acids of the human immunodeficiency virus TAT transporter 
sequence to the 21 amino-acid sequence corresponding to ADAM10 
proline-rich domains (NH2-YGRKKRRQRRRPKLPPPKPLPGTLKRR-
RPPQP-COOH). TAT-Ala-ADAM10709–729 peptide, in which all pro-
line residues were mutated into alanine (NH2-YGRKKRRQRRRAK-
LAAAKALAGTLKRRRAAQA-COOH), was used as control (27, 28). 
The TAT-Pro-ADAM10709–729 inhibitory peptide and TAT-Ala-AD-
AM10709–729 control peptide were generated by PolyPeptide and were 
maintained at 4°C while lyophilized. Once solubilized, solutions were 
maintained at –20°C for a maximum of 1 week. For biochemical anal-
yses, animals were euthanized 24 hours after the second injection by 
dislocation and the brains were rapidly removed for dissection of stri-
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HEK393T transfection and coimmunoprecipitation. cDNAs encod-
ing for human full-length HTT-HA bearing 23 or 83 CAG repeats and 
for human ADAM10-3XFLAG were synthesized by GenScript and 
subcloned into pCDNA3.1 vectors. 10 Million cells were transfected 
with 8 μg of cDNA encoding human HTT and 8 μg of cDNA encoding 
human ADAM10-3XFLAG or pCDNA3.1 empty vector by using the 
Lipofectamine 3000 protocol (Invitrogen, Thermo Fisher Scientific, 
catalog L300-015). Cell pellets were lysed at 48 hours after transfec-
tion, using as a lysis buffer PBS containing 0.4% Triton X-100 and 1× 
protease inhibitor cocktail (Thermo Scientific, catalog 1861281) and 
centrifuged (12,000 g per 15 minutes at 4°C). Supernatant was quan-
tified for total protein content with the BCA method (Thermo Fisher 
Scientific, Pierce BCA Protein Assay Kit, catalog 23225). Immuno-
precipitation was performed using Dynabeads Protein G (Thermo 
Fisher Scientific, catalog 10004D) according to the manufacturer’s 
instructions. Protein lysate (400 μg) was incubated with 10 μg of 
mouse monoclonal anti–FLAG-specific antibody (Invitrogen, Ther-
mo Fisher Scientific, catalog MA1-91878) for 1 hour at 4°C on a rota-
tion wheel and then loaded onto 20 μl of Dynabeads (Thermo Fisher 
Scientific, catalog 10004D) and incubated for 1 hour at room tem-
perature on a rotation wheel. After washing, the beads were eluted 
in 20 μl/sample of loading buffer 4× (125 mM Tris-HCl pH 6.8, 6% 
SDS, 4 M urea, 4 mM EDTA, 30% glycerol, 4% 2-mercaptoethanol, 
and bromophenol blue). For Western blot, samples were denatured 
at 95°C and loaded on a 10% SDS-PAGE gel. Separated proteins were 
transferred onto a nitrocellulose membrane (Biorad Turbo Nitrocel-
lulose, catalog 1704158) by means of the Trans-blot Turbo Transfer 
System (Bio-Rad) (protocol: 1.5 A constant; up to 25 V; 20 minutes). 
Membranes were blocked with 5% nonfat milk in TBST for 1 hour and 
were then incubated overnight at 4°C with rabbit monoclonal anti-HA 
(1:1000; Cell Signalling, catalog C29F4), anti-FLAG (1:1000; Invit-
rogen, Thermo Fisher Scientific, catalog MA1-91878), and mouse 
monoclonal anti α-Tubulin (1:5000; MilliporeSigma, catalog T9026) 
antibodies in TBST. After washing, filters were incubated for 1 hour 
at room temperature with secondary antibodies (1:3000; Bio-Rad, 
goat anti-rabbit HRP, catalog 1706515, goat anti-mouse HRP, catalog 
1706516) prepared in 5% milk in TBST. The Clarity Western ECL Sub-
strate (Bio-Rad, catalog 1705061) was used to visualize immunoreac-
tive bands. Blot visualization was performed by using the ChemiDoc 
MP Imaging System (Bio-Rad).
RNA preparation and retrotranscription. Total RNA was isolated 
from 200–300 mg of mouse tissue using 2 ml TRIzol reagent (Invit-
rogen, Thermo Fisher Scientific, catalog 15596026) after the tissues 
had been homogenized in liquid nitrogen with a mortar and pestle. To 
enhance RNA yield, the samples were precipitated by adding 2 μl glyco-
gen solution (10 mg/ml) to isopropanol and incubating them at –80°C 
overnight. The concentration of RNA was evaluated spectrophoto-
metrically, and its quality was verified by means of agarose gel electro-
phoresis of 1 μg of each sample. Genomic DNA was digested using 1 U 
rDNaseI (Invitrogen, Thermo Fisher Scientific, catalog AM1906) per 
1 μg/μl of total RNA and incubated at 37°C for 10 minutes following 
the manufacturer’s instructions. The total RNA was stored in aliquots 
at –80°C. Total RNA (1 μg) was reverse transcribed to single-stranded 
cDNA using Superscript III RNaseH reverse transcriptase (Invitrogen, 
Thermo Fisher Scientific, catalog 18080-044) and random primers 
(Invitrogen, Thermo Fisher Scientific, catalog 48190-011) in a volume 
of 20 μl, according to the manufacturer’s instructions.
4°C. The resulting supernatant was collected. Protein concentration 
was determined with the BCA assay (Thermo Fisher Scientific, catalog 
23225) and 20–60 μg was loaded on a 10% SDS-PAGE gel. Separated 
proteins were transferred onto a nitrocellulose membrane (Bio-Rad 
Turbo Nitrocellulose, catalog 1704158) by means of the Trans-blot Tur-
bo Transfer System (Bio-Rad) (standard protocol: 1.5 A constant; up to 
25 V; 10 minutes), blocked with 5% nonfat dry milk (Bio-Rad, catalog 
1706404) in TBS and 0.1% Tween 20 (TBST), and incubated with pri-
mary antibodies at room temperature for 3 hours or at 4°C overnight. 
After washing, filters were incubated for 1 hour at room temperature 
with a peroxidase conjugate secondary antibody (1:3000; Bio-Rad, 
goat anti-rabbit HRP, catalog 1706515, goat anti-mouse HRP, catalog 
1706516) and then washed 3 times with TBS and 0.1% Tween 20. The 
Clarity Western ECL Substrate (Bio-Rad, catalog 1705061) was used 
to visualize immunoreactive bands. Blot visualization was performed 
by using the ChemiDoc MP Imaging System from Bio-Rad. Densito-
metric analyses were performed by using Image Lab 4.1 software. The 
primary antibodies and dilutions used for the Western blot were as 
follows: mouse monoclonal anti–N-CAD (1:1000; Becton Dickinson 
Transduction Laboratories, catalog 610921); mouse monoclonal anti 
α-Tubulin (1:5000; MilliporeSigma, catalog T9026); rabbit polyclonal 
anti-ADAM9 (1:1000; Enzo Life Science, catalog SA-376); rabbit poly-
clonal anti-ADAM10 and anti-ADAM17 (1:1000; provided in house). 
The ADAM10 antibody was validated by using ADAM10-knockout 
brain tissues: a 75 kDa nonspecific signal was revealed.
Isolation of TIF and synaptosomes. For the isolation of TIF-PSD 
fractions from striatal and cortical tissues of WT and R6/2 at 6 and 
12 weeks of age, mouse tissue homogenization was carried out by 10 
strokes in a Teflon-glass homogenizer (clearance 0.25 mm, 700 rpm) 
in 4 ml/g wet weight cold 0.32 M sucrose solution containing 1 mM 
Hepes pH 7.4, 1 mM MgCl2, 1 mM EDTA pH 8, 1 mM NaHCO3, 0.1 mM 
PMSF, and 1× protease inhibitors (Thermo Fisher Scientific, catalog 
1861281). The homogenized tissue was centrifuged at 2,300 g for 10 
minutes at 4°C. The resulting supernatant was centrifuged at 13,000 
g for 30 minutes at 4°C, and the pellet was resuspended in a solution 
of 75 mM KCl, 1% Triton X-100, 0.1 mM PMSF, and 1× protein inhib-
itors and centrifuged at 100,000 g for 2 hours at 4°C. The pellet was 
resuspended in 50 mM HEPES pH 7.4 and 5% glycerol. From 20 to 
30 μg TIF-PSD enriched fraction was loaded on a 10% SDS-PAGE gel. 
Separated proteins were transferred onto a nitrocellulose membrane 
(Bio-Rad Turbo Nitrocellulose, catalog 1704158) by means of the 
Trans-blot Turbo Transfer System (Bio-Rad) (standard protocol: 1.5 A 
constant; up to 25 V; 10 minutes), blocked with 5% nonfat dry milk 
(Bio-Rad, catalog 1706404) in TBS and 0.1% Tween 20, and incubat-
ed with primary antibodies at room temperature for 3 hours or at 4°C 
overnight. The primary antibodies used for Western blot on PSD frac-
tions were as follows: rabbit polyclonal anti-ADAM10 (1:1000; provid-
ed in house); mouse monoclonal anti–βIII-Tubulin (1:1000; Promega, 
catalog G712A); mouse monoclonal anti-PSD95 antibody (1:2000; 
Thermo Fisher Scientific, catalog 6G6-1C9). Synaptosomes from WT, 
R6/2, R6/2-A10cKO, and from human postmortem tissues were pre-
pared by using Syn-PER Reagent (Thermo Scientific, catalog 87793) 
according to the manufacturer’s instructions. Samples containing 
equal amounts of protein lysates were loaded on 10% SDS-PAGE gels, 
and blots were probed with rabbit polyclonal anti-ADAM10 (1:1000; 
provided in house) and/or with anti-ADAM10 antibody EPR5622 
(1:1000; Abcam, catalog ab124695).
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added to the aCFS medium. The EPSC recordings were carried out 
at the holding potential of –70 mV and in the presence of 10 μM bicu-
culline (Sigma-Aldrich, catalog 14343). Miniature EPSCs (mEPSCs) 
were derived in the presence of 1 μM TTX (Sigma-Aldrich, catalog 
T8024). To test the effect of 50 nM GI254023X, slices were incubat-
ed with the drug for 45 minutes before and during the recording. Data 
were analyzed with the software Clampfit 10.2 (Molecular Devices) 
and Origin (Microcal). Cell surface was estimated by integrating the 
capacitive current evoked by a −10 mV pulse. Neuronal Rin was calcu-
lated in the linear portion of the I-V relationship during depolarizing 
voltage responses near the Vm. The EPSCs were detected manually: 
the amplitude of the events obeyed a log-normal distribution and, 
accordingly, the mean amplitudes were computed using a log-normal 
function; the interevent intervals were distributed exponentially, and 
mean frequencies were obtained from the best monoexponential fit 
of each distribution.
Electron microscopy. Mice were anesthetized with 10 mg/ml aver-
tin and transcardially perfused using 2.5% glutaraldehyde (Electron 
Microscopy Sciences, catalog 16220), and 2% paraformaldehyde 
(Electron Microscopy Sciences, catalog 19200) as fixatives, both in 
sodium cacodylate buffer 0.15 M (pH 7.4) (Electron Microscopy Sci-
ences, catalog 12300). Brains were removed and post-fixed for an 
additional 24 hours at 4°C, and 100 μm thick coronal slices were cut 
by using a Leica VT1000S Vibratome. Sections were collected in 0.1 
M sodium cacodylate buffer, and striatum was manually dissected 
for staining and embedding. Samples were then washed with 0.1 M 
cold sodium cacodylate buffer and then postfixed in a reduced osmi-
um solution (i.e., 1.5% potassium ferrocyanide, Electron Microscopy 
Sciences, catalog 20150) with 2% osmium tetroxide (Electron Micros-
copy Sciences, catalog 19170) in 0.15 M cacodylate buffer for 1 hour 
on ice. After the first heavy metal incubation, the tissues were washed 
with ddH2O at room temperature and then placed in the 0.22 μm Mil-
lipore-filtered 1% thiocarbohydrazide (TCH) (Electron Microscopy 
Sciences, catalog 21900) in ddH2O solution for 20 minutes at room 
temperature. Tissues were then rinsed again in ddH2O and incubated 
in 2% osmium tetroxide in ddH2O for 30 minutes at room tempera-
ture. After several washings at room temperature in ddH2O, they were 
then placed in 1% uranyl acetate (aqueous) and left overnight at 4°C. 
Samples were washed once again and then immersed en bloc in Wal-
ton’s lead aspartate solution (0.066 gr lead nitrate, Electron Micros-
copy Sciences, catalog 17900) dissolved in 10 ml of 0.003 M aspartic 
acid solution, pH 5.5) at 60°C for 30 minutes. The tissues were washed 
and then dehydrated stepwise through an ethanol series and finally 
placed in anhydrous ice-cold acetone for 10 minutes. Infiltration was 
performed with an acetone (Sigma-Aldrich, catalog 179124)/Durcu-
pan ACM (Electron Microscopy Sciences, catalog 14040) mixture 
with 3:1 volume proportions for 2 hours, then 1:1 overnight. The tissues 
were left for 2 hours in pure resin and then embedded in Durcupan 
ACM resin and placed in a 60°C oven for 48 hours for polymerization. 
For TEM imaging, ultrathin sections 70 nm thick were prepared by 
an UltraCut E Ultramicrotome (Reichert) and placed on TEM copper 
grids, which were then observed using a LEO 912AB microscope (Carl 
Zeiss) equipped with a thermionic W electron source and operating at 
an acceleration voltage of 100 kV. For quantitative analyses, images 
(resolution: 1024 × 1024 pixels) were acquired using a bottom mount 
Esivision CCD-BM/1K system (ProScan Camera). Quantitative mea-
surements were performed by ImageJ, version 1.47 (NIH), and mea-
Real-time PCR. We used an iCycler Thermal Cycler with a Multi-
colour Real-time PCR Detection System (Bio-Rad). All reactions were 
performed in a total volume of 25 μl with 5 μl of cDNA, 20 μl iQTM 
SYBR Green Supermix (Bio-Rad, catalog 17088 80), and 0.2 μM each 
of forward and reverse primers. The amplification consisted of the fol-
lowing: 95°C for 3 minutes, 45 cycles of 30 seconds at 95°C, 30 sec-
onds at 60°C, and 30 seconds at 72°C. Fluorescence was quantified 
during the annealing step, and product formation was confirmed by 
melting curve analysis (55°C–94°C). The following primers were used: 
ADAM10 forward: GGAAGCTTTAGTCATGGGTCTG; ADAM10 
reverse: CTCCTTCCTCTACTCCAGTCAT; β-actin forward: AGT-
GTGACGTTGACATCCGTA; β-actin reverse: GCCAGAGCAGTA-
ATCTCCTTCT; h18S forward: CGGCTACCACATCCAAGGAA; h18S 
reverse: GCTGGAATTACCGCGGCT; and hHTT forward: CGC-
TATGGAACTTTTTCTGCTGTG; hHTT reverse: CTGTAACCTTG-
GAAGATTAGAATCCATC. Data were analyzed by using the software 
Bio-Rad CFX Manager V.1.6.541.1028.
Brain slice preparation for biochemistry and electrophysiology. Acute 
brain slices were prepared from 11- to 12-week-old WT and R6/2 mice 
and from 54-week-old WT and zQ175 mice. For biochemical experi-
ments, mice were anesthetized by i.p. injection of 10 mg/ml avertine 
and perfused in PBS 1×. After brain dissection, 300 μm thick coronal 
slices were cut on a Vibratome (Leica, catalog VT1000S) in cold PBS 
solution supplemented with 15 mM glucose, placed on membrane 
inserts, and incubated in Petri dishes with aCSF containing 125 mM 
NaCl, 2.5 mM KCl, 25 mM NaHCO3, 1.25 mM NaH2PO4, 6 mM MgCl2, 
2 mM CaCl2, and 10 mM glucose. Brain slices were incubated with 
GI254023X at concentrations of 1, 10, 100, and 1000 nM for 45 min-
utes at 37°C and total protein lysates were prepared for Western blot 
as previously described. For electrophysiology experiments, animals 
were anesthetized by inhalation of isoflurane and transcardially per-
fused with cold (<4°C), carboxygenated (95% O2, 5% CO2) cutting 
solution (70 mM sucrose, 80 mM NaCl, 2.5 mM KCl, 26 mM NaHCO3, 
15 mM glucose, 7 mM MgCl2, 1 mM CaCl2, 1.25 mM NaH2PO4). Cor-
onal 300 μm thick slices were transferred to an incubation chamber 
filled with carboxygenated aCSF medium (125 mM NaCl, 2.5 mM 
KCl, 26 mM NaHCO3, 15 mM glucose, 1.3 mM MgCl2, 2.3 mM CaCl2, 
1.25 mM NaH2PO4). For electrophysiological studies, GI254023X was 
used at concentrations of 50 nM for 45 minutes. All recordings were 
performed at 23–25°C on submerged slices perfused at 0.6 ml/min-
utes with aCSF. The recording chamber was mounted on an E600FN 
microscope equipped with a 4× lens and a 40× water-immersion 
objective (Nikon) and connected to a near-infrared CCD camera. 
The data were derived from striatal MSNs using the whole-cell patch-
clamp technique in voltage- and current-clamp mode. Pipettes were 
produced from borosilicate glass capillary tubes (Hilgenberg GmbH) 
by means of a horizontal puller (P-97, Sutter Instruments) and filled 
with the following intracellular solution: 130 mM K-gluconate, 4 mM 
NaCl, 2 mM MgCl2, 1 mM EGTA, 5 mM creatine phosphate, 2 mM 
Na2ATP, 0.3 mM Na3GTP, and 10 mM HEPES (pH 7.3 with KOH). 
Membrane voltage was corrected off-line for a measured liquid junc-
tion potential. Series resistance was always compensated by 70%–
90% and monitored throughout the experiment. Recordings were 
made with a MultiClamp 700B amplifier (Molecular Devices) and 
digitized with a Digidata 1322 computer interface (Molecular Devic-
es). Data were acquired using the software Clampex 9.2 (Molecular 
Device), sampled at 20 kHz, and filtered at 10 kHz. All drugs were 
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while 1-way ANOVA followed by the nonparametric Dunn’s multiple 
comparison test was used when more than 2 groups were tested. Differ-
ences were considered statistically significant at P < 0.05.
Study approval. All protocols involving animals were carried out in 
accordance with institutional guidelines in compliance with Italian law 
(D. Lgs no. 2014/26, implementation of the 2010/63/UE). The Ethics 
Committee of the University of Milano approved studies in mice (Eth-
ics Committee 09.10.13, Ethical Approval 74/13; Ethics Committee 
18.12.13, Ethical Approval 74/14) and the use of human postmortem 
samples obtained from HBTRC (Ethics Committee 18.12.13, Ethical 
Approval 74/14).
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suring the following parameters: SVs number per area unit (μm2), 
number of docked vesicles per active zone (AZ), AZ length (μm), and 
PSD length (nm). For SBF-SEM imaging, resin blocs were mounted 
on aluminium specimen pins and trimmed with a glass knife using an 
Ultramicrotome in order to expose the tissue on all 4 sides. Silver paint 
(TedPella, catalog 16031) was used to electrically ground the edges of 
the tissue block to the aluminium pin. The entire specimen was then 
sputter coated with a thin layer of gold in order to finely mount it into 
the SEM chamber in view of the SBF-SEM imaging. The blocks con-
taining striatum were imaged using a Gatan 3View system (Gatan) 
attached to a FEI Quanta FEG 200 SEM equipped with a Schottky 
field emission electron source, operating at an accelerating voltage of 
3 kV, and with a beam current of 21 pA, upon low-vacuum conditions 
(15 Pa). Serial SEM images were acquired collecting the backscattered 
electron (BSE) signal, with a magnification of ×10,000, a dwell time 
of 10 μs per pixel, and an image resolution of 2048 × 2048 pixels, cor-
responding to a final asymmetric voxel size of 6.7 × 6.7 × 50 nm3. For 
3D reconstruction, rendering, and analysis, serial SEM images were 
assembled into volume files aligned using Digital Micrograph (Gatan). 
For manual segmentation and 3D model generation, electron micros-
copy image stacks were then converted to 8-bit grayscale tiff format 
images and manually segmented using the AMIRA software package 
(FEI Company). 3D structures in image stacks containing hundreds or 
thousands of 2D orthoslices were traced individually in each plane and 
automatically surface rendered. The PSD volume was measured by 
the AMIRA 3D model using its Material Statistics module. The excit-
atory synapse density (n of excitatory synapse/μm3) was measured by 
using Ilastik-0.5.12 software.
In vitro metalloprotease assay. The ADAM10 inhibitor GI254023X 
and ADAM17 inhibitor GW280264X were serially diluted in DMSO and 
transferred to a 384-well plate in a volume suitable to reach the desired 
compound concentrations in 20 μl of reaction buffer (TrisHCl 25 mM 
pH 9.0, 0.005% Brij-35, 2.5 μM ZnCl2, 100 mM NaCl). ADAM10 (R&D 
Systems, catalog CF936-AD-020) was used at a final concentration 
of 2.5 nM, while ADAM17 (R&D Systems, catalog 930-ADB-010) was 
used at 1 nM. For both assays, the BML-P235-0001 substrate (Enzo Life 
Sciences) was used at 10 μM. The reaction was incubated at room tem-
perature for 1 hour; then the cleaved substrate was revealed by flores-
cence intensity according to the manufacturer’s protocol.
Statistics. All measurements are presented as mean ± SEM. Prism 
7.0c (GraphPad Software) was used to perform all statistical analyses. 
For each set of data to be compared, we determined in Prism whether 
data were normally distributed or not by using the D’Agostino-Pearson 
or Shapiro-Wilk normality test. For normally distributed values, statisti-
cal significance was determined by the unpaired Student’s t test when 2 
groups were compared while 1-way ANOVA followed by Newman-Keuls 
or Bonferroni’s multiple comparison test was used when more than 2 
groups were tested. For nonnormal distributed data, the nonparametric 
Mann-Whitney 2-tailed U test was used when 2 groups were compared, 
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